Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Feb;36(1):409-415.
doi: 10.21873/invivo.12718.

Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer

Takaaki Arigami  1 , Daisuke Matsushita  2 , Keishi Okubo  2 , Takako Tanaka  2 , Ken Sasaki  2 , Yusuke Tsuruda  2 , Yoshiaki Kita  2 , Shinichiro Mori  2 , Hiroshi Kurahara  2 , Yoshikazu Uenosono  2 , Takao Ohtsuka  3   2
Affiliations

Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer

Takaaki Arigami et al. In Vivo. 2022 Jan-Feb.

Abstract

Background/aim: To investigate changes in post-progression chemotherapy (PPC) before and after nivolumab approval and determine their prognostic impact.

Patients and methods: A total of 146 patients with unresectable gastric cancer who had at least progressive disease after first- and/or second-line chemotherapy were retrospectively enrolled.

Results: Among the 146 patients, 46 and 23 received ramucirumab and nivolumab, respectively. Moreover, 95 and 62 patients received PPC after first- and second-line chemotherapy, respectively. Group B (i.e., at least chemotherapy after nivolumab approval) had significantly higher proportions of patients receiving ramucirumab therapy, nivolumab therapy, and PPC after first- or second-line chemotherapy compared to group A (i.e., termination of chemotherapy before nivolumab approval). Group A had significantly poorer prognosis than group B. Multivariate analysis showed that age, number of distant metastatic sites, and ramucirumab therapy were independent prognostic factors.

Conclusion: Changes in chemotherapeutic strategies, including PPC, might contribute to improved prognosis in patients with advanced gastric cancer.

Keywords: Post-progression chemotherapy; gastric cancer; nivolumab; prognosis; ramucirumab.

PubMed Disclaimer

Conflict of interest statement

All Authors have no conflicts of interest to disclose in relation to this study.

Figures

Figure 1
Figure 1. The proportion of patients receiving post-progression chemotherapy after first- or second-line chemotherapy. A) after first-line chemotherapy. B) after second-line chemotherapy.
Figure 2
Figure 2. Kaplan-Meier survival curves according to nivolumab approval status.
See this image and copyright information in PMC

References

    1. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, Ono H, Tanabe S, Kaminishi M. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27. doi: 10.1007/s10120-012-0163-4. - DOI - PMC - PubMed
    1. Kim SG, Seo HS, Lee HH, Song KY, Park CH. Comparison of the differences in survival rates between the 7th and 8th editions of the AJCC TNM staging system for gastric adenocarcinoma: a single-institution study of 5,507 patients in Korea. J Gastric Cancer. 2017;17(3):212–219. doi: 10.5230/jgc.2017.17.e23. - DOI - PMC - PubMed
    1. Shitara K, Ohtsu A. Advances in systemic therapy for metastatic or advanced gastric cancer. J Natl Compr Canc Netw. 2016;14(10):1313–1320. doi: 10.6004/jnccn.2016.0138. - DOI - PubMed
    1. Arai H, Nakajima TE. Recent developments of systemic chemotherapy for gastric cancer. Cancers (Basel) 2020;12(5):1100. doi: 10.3390/cancers12051100. - DOI - PMC - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi: 10.1016/S0140-6736(10)61121-X. - DOI - PubMed

MeSH terms